Fewer patients in the rolapitant 180 mg group required rescue medication (14 %) compared with active control (25 %). Time to first emesis or to rescue medication use was significantly longer during cycle 1 for patients treated with rolapitant 180 mg compared with active control (p=0.011;
Fig. 3).